Phase I study to investigate the safety and efficacy of TUR-002 for the treatment of Major Depressive Disorder (MDD).

Trial Profile

Phase I study to investigate the safety and efficacy of TUR-002 for the treatment of Major Depressive Disorder (MDD).

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2016

At a glance

  • Drugs Ketamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jan 2016 Status changed from planning to not yet recruiting, as reported in a Turing Pharmaceuticals media release.
    • 08 Jan 2016 New trial record
    • 12 Nov 2015 According to the media release of Turing Pharmaceuticals, this trial is planned to initiate by first quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top